Skip to main content

puxitatug samrotecan

Generic: Puxitatug Samrotecan

puxitatug samrotecan: 2 clinical trials tracked.

puxitatug samrotecan evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about puxitatug samrotecan, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence3 indications · 1 study sponsors
Clinical Trial Registry Records (2)

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4 Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (Bluestar-Endometrial01)

NCT07044336Registry updated 2026-07-29·Phase 3·AZN
Recruiting

Primary endpoint: Progression Free Survival (PFS) for Arm A vs Arm B

InterventionalRandomizedsingle800 targetStarted 2025-08Completion 2029-0750 sites · United StatesAstraZeneca

A Phase I/IIa Multi-center, Open-label Master Protocol Dose Escalation and Expansion Study of AZD8205 as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors (BLUESTAR)

NCT05123482Registry updated 2026-09-11·Phase 1/Phase 2·AZN
Recruiting

Primary endpoint: The number of patients with adverse events

InterventionalRandomizedopen460 targetStarted 2021-10Completion 2027-0950 sites · Australia, Belgium, Canada, China…AstraZeneca